We serve Chemical Name:cis-jasmonolactone CAS:70851-61-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:cis-jasmonolactone
CAS.NO:70851-61-5
Synonyms:4-methyl-cis-decenegamma-lactone;LACTONE OF CIS JASMONE;4-hydroxy-4-methyl-7-cis-decenoicacidlactone;JASMOLACTONE CIS;FEMA 3937;4-Methyl-4-hydroxy-cis-7-decenoicacidlactone
Molecular Formula:C11H18O2
Molecular Weight:182.25900
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:281.6ºC at 760 mmHg
Density:0.949g/cm3
Index of Refraction:1.461
PSA:26.30000
Exact Mass:182.13100
LogP:2.82850
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 4-methyl-cis-decenegamma-lactone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Methyl-4-hydroxy-cis-7-decenoicacidlactone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,JASMOLACTONE CIS Use and application,JASMOLACTONE CIS technical grade,usp/ep/jp grade.
Related News: With the advancement of supply-side structural reforms, the production of bulk APIs in China will become more concentrated, and the technology will be further improved. cis-jasmonolactone manufacturer We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally. cis-jasmonolactone supplier The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances. cis-jasmonolactone vendor As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. cis-jasmonolactone factory With the advancement of supply-side structural reforms, the production of bulk APIs in China will become more concentrated, and the technology will be further improved.
